Momordica charantia L. for hyperlipidaemia: A randomised controlled assessment of the Ghanaian herbal medicinal product MCP-1

Simple item page
dc.contributor.authorKwesi Prah, Thomford
dc.contributor.authorAma Kyeraa, Thomford
dc.contributor.authorYorke, Joseph
dc.contributor.authorYeboah, Ronald
dc.contributor.authorAppiah, Alfred Ampomah
dc.contributor.orcid0000-0002-5229-0340
dc.date.accessioned2024-05-29T15:14:26Z
dc.date.available2024-05-29T15:14:26Z
dc.date.issued2021
dc.descriptionThis article is published by Elsevier and is also available at https://doi.org/10.1016/j.hermed.2021.100453
dc.description.abstractCardiovascular diseases are a public health burden for developing countries like Ghana. Scientifically validated herbal medicines are viable options in the prevention and treatment of such conditions. In this study, a rand omised controlled trial involving 15 healthy subjects identified with hyperlipidaemia was undertaken. Treatment comprised a traditional Ghanaian herbal formulation prepared from the leaves and twines of Momordica char antia (MCP-1) with a standard dietary guideline. A control group was managed using a standard dietary guideline alone. In all, 15 subjects completed the study: MCP-1 had 10 subjects and 5 subjects in the control group. At the termination of the trial after 8 weeks, reduction in lipoprotein values were recorded for all participants. In the MCP-1 group, triglycerides reduced by 3.46 % compared to 3.37 % for the control while total cholesterol was also reduced by 9.78 % and 9.43 % in the MCP-1 and control groups respectively. High density lipoproteins (HDL) levels increased by 6.92 % for MCP-1 and 3.92 % for the control group. However, these changes were not statistically significant except in the instance of the low-density lipoproteins (LDL-c; CI: -41.24 to -19.76) and very low-density lipoproteins (VLDL-c; CI: -26.87 to -8.192). Changes to other disease indices such as blood pressure (BP), fasting blood sugar (FBS) and body mass index (BMI) were also not different between the 2 groups. MCP-1 was well tolerated among the subjects and was shown to be safe from the biochemical and haematological indicators. The product, MCP-1 has therefore been shown to be a safe and prospective anti-lipidaemic agent.
dc.description.sponsorshipKNUST
dc.identifier.citationJournal of Herbal Medicine 28 (2021) 100453
dc.identifier.uri10.1016/j.hermed.2021.100453
dc.identifier.urihttps://ir.knust.edu.gh/handle/123456789/15740
dc.language.isoen
dc.publisherElsevier
dc.titleMomordica charantia L. for hyperlipidaemia: A randomised controlled assessment of the Ghanaian herbal medicinal product MCP-1
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Momordica charantia L. for hyperlipidaemia A randomised controlled.pdf
Size:
852.42 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed to upon submission
Description:
Download
Collections
Articles